Hederacoside C

• CAT Number: I001626
• CAS Number: 14216-03-6
• Molecular Formula: C59H96O26
• Molecular Weight: 1221.38
• Purity: ≥95%
• Target: MAPK/ERK Pathway
• Storage: 2-8°C
• IUPAC Name: [(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
• InChI: InChI=1S/C59H96O26/c1-24-34(63)38(67)42(71)49(78-24)83-46-29(20-60)80-48(45(74)41(46)70)77-22-30-37(66)40(69)44(73)51(81-30)85-53(75)59-17-15-54(3,4)19-27(59)26-9-10-32-55(5)13-12-33(56(6,23-61)31(55)11-14-58(32,8)57(26,7)16-18-59)82-52-47(36(65)28(62)21-76-52)84-50-43(72)39(68)35(64)25(2)79-50/h9,24-25,27-52,60-74H,10-23H2,1-8H3/t24-,25-,27-,28-,29+,30+,31+,32+,33-,34-,35-,36-,37+,38+,39+,40-,41+,42+,43+,44+,45+,46+,47+,48+,49-,50-,51-,52-,55-,56-,57+,58+,59-/m0/s1
• InChIKey: RYHDIBJJJRNDSX-MCGLQMIESA-N
• SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)[C@@]45CC[C@@]6(C(=CC[C@H]7[C@]6(CC[C@@H]8[C@@]7(CC[C@@H]([C@@]8(C)CO)O[C@H]9[C@@H]([C@H]([C@H](CO9)O)O)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)C)C)[C@@H]4CC(CC5)(C)C)C)O)O)O)CO)O)O)O

Hederacoside C（Cat No.:I001626）is a bioactive compound found in the leaves of Hedera helix (common ivy), and it serves as a principal pharmaceutical ingredient with potential therapeutic applications for respiratory disorders. This compound exhibits several beneficial effects, including expectorant properties, which help in the expulsion of respiratory secretions, bronchodilation, which aids in widening the airways, antibacterial activity, and bronchospasmolytic effects, which reduce bronchial spasms. These combined properties make Hederacoside C a promising candidate for the treatment of respiratory conditions by promoting mucus clearance, alleviating bronchial constriction, and fighting against bacterial infections.

Reference

[1]. Rehman SU et al. An ultra-high-performance liquid chromatography-tandem mass spectrometric method for the determination ofhederacoside C, a drug candidate for respiratory disorder, in rat plasma. J Pharm Biomed Anal. 2016 Jun 24;129:90-95.

[2]. Kim JM et al. Pharmacokinetics of hederacoside C, an active ingredient in AG NPP709, in rats. Xenobiotica. 2013 Nov;43(11):985-92.